Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028

MARKET OUTLOOK

As per this research on the non-alcoholic steatohepatitis (NASH) biomarker market in Europe, the market is likely to witness progress at a compound annual growth rate of 20.19% in the years 2021-2028. France, the United Kingdom, Italy, Spain, Russia, Germany, and Rest of Europe outline the overall region's market.
Among the region's nations, the prevalence of non-alcoholic steatohepatitis is relatively less in Italy compared to other countries. However, there is a rise in the number of non-alcoholic fatty liver disease cases, which will increase the incidence of NASH in the next few years. Moreover, the mortality rate due to liver diseases is assessed to surge across the country, owing to the aging population's increase. Above all, obesity and diabetes are primary conditions leading to the development of NASH among people. Thus, this growth in liver diseases is probable to amplify the progress of the NASH biomarker market over the forecast period across Italy.

Similarly, the surge in diabetics and obesity levels have increased the demand for advanced medical services in Russia. Moreover, Russia ranked fifth in the top ten countries with the highest diabetes levels. This growth in the number of people suffering from diabetes and obesity results in severe conditions, including non-alcoholic steatohepatitis, increasing the demand for healthcare services. Hence, the rise in healthcare services, along with healthcare expenditure, is calculated to augment the expansion of the non-alcoholic steatohepatitis biomarker market within Russia in the near future.

COMPETITIVE OUTLOOK

The distinguished enterprises in the non-alcoholic steatohepatitis (NASH) biomarker market include Bristol Myers Squibb Company, Genfit SA, Gilead Sciences Inc, Novartis AG, Madrigal Pharmaceuticals, and Merck & Co.

1. Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Summary

2. Industry Outlook

2.1. Key Insights
2.1.1. Demand for NASH Biomarkers
2.1.2. Unmet Medical Needs
2.2. Impact of COVID-19 on Non-Alcoholic Steatohepatitis (NASH) Biomarker Market
2.3. Porter's Five Forces Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute Products
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Competitive Rivalry
2.4. Market Attractiveness Index
2.5. Vendor Landscape
2.6. Key Market Strategies
2.6.1. Contracts & Partnerships
2.6.2. Business Expansions & Divestitures
2.6.3. Acquisitions & Mergers
2.6.4. New Product Launches
2.7. Market Drivers
2.7.1. Rising Prevalence of NASH
2.7.2. Increasing Incidence Rate of Metabolic Comorbidities
2.8. Market Restraints
2.8.1. Side-Effects of NASH Therapeutics
2.8.2. Unavailability of Specialized Diagnostic Test for Non-Alcoholic Fatty Liver Disease (Nafld)
2.9. Market Opportunities
2.9.1. Rise in Awareness Pertaining to Non-Alcoholic Fatty Liver Disease

3. Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Type

3.1. Serum Biomarker
3.2. Hepatic Fibrosis Biomarker
3.3. Apoptosis Biomarker
3.4. Oxidative Stress Biomarker
3.5. Other Types

4. Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Industry Verticals

4.1. Pharma & Cro Industry
4.2. Diagnostic Lab
4.3. Academic Research Key
4.4. Hospital

5. Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Country Outlook

5.1. Germany
5.2. France
5.3. United Kingdom
5.4. Italy
5.5. Russia
5.6. Spain
5.7. Rest of Europe

6. Competitive Landscape

6.1. Allergan
6.2. Astrazeneca
6.3. Bristol Myers Squibb Company
6.4. Genfit Sa
6.5. Gilead Sciences Inc
6.6. Madrigal Pharmaceuticals
6.7. Merck & Co
6.8. Novartis AG
6.9. Novo Nordisk
6.10. Pfizer Inc
6.11. Siemens Healthineers
6.12. Viking Therapeutics
6.13. Zydus Cadila

7. Research Methodology & Scope

7.1. Research Scope & Deliverables
7.1.1. Objectives of Study
7.1.2. Scope of Study
7.2. Sources of Data
7.2.1. Primary Data Sources
7.2.2. Secondary Data Sources
7.3. Research Methodology
7.3.1. Evaluation of Proposed Market
7.3.2. Identification of Data Sources
7.3.3. Assessment of Market Determinants
7.3.4. Data Collection
7.3.5. Data Validation & Analysis

List of Tables

Table 1: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
Table 2: Vendor Landscape
Table 3: List of Contracts & Partnerships
Table 4: List of Business Expansions & Divestitures
Table 5: List of Acquisitions & Mergers
Table 6: List of New Product Launches
Table 7: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 8: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 9: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)

List of Figures

Figure 1: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 2: Porter's Five Forces Analysis
Figure 3: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2020 & 2028 (In %)
Figure 4: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Serum Biomarker, 2021-2028 (In $ Million)
Figure 5: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Hepatic Fibrosis Biomarker, 2021-2028 (In $ Million)
Figure 6: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Apoptosis Biomarker, 2021-2028 (In $ Million)
Figure 7: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Oxidative Stress Biomarker, 2021-2028 (In $ Million)
Figure 8: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Other Types, 2021-2028 (In $ Million)
Figure 9: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2020 & 2028 (In %)
Figure 10: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Pharma & Cro Industry, 2021-2028 (In $ Million)
Figure 11: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Diagnostic Lab, 2021-2028 (In $ Million)
Figure 12: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Academic Research Key, 2021-2028 (In $ Million)
Figure 13: Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Hospital, 2021-2028 (In $ Million)
Figure 14: Germany Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 15: France Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 16: United Kingdom Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 17: Italy Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 18: Russia Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 19: Spain Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 20: Rest of Europe Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)